Tuberoinfundibular peptide of 39 residues decreases pain-related affective behavior

NeuroReport

Volumn 15, Issue 11, 2004, Pages 1779-1782

  LaBuda, Christopher J ^a,b   Usdin, Ted B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ADOLOR CORPORATION   (United States)

Author keywords

Affect; Behavior; Hot plate; Inflammation; Neuropeptide; Pain; Parathyroid hormone 2 receptor; Place escape avoidance paradigm

Indexed keywords

ANALGESIC AGENT; CARRAGEENAN; LIGAND; TUBEROINFUNDIBULAR PEPTIDE 39; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; AVERSIVE BEHAVIOR; CONTROLLED STUDY; HOT PLATE TEST; MALE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT;

ANIMALS; AVOIDANCE LEARNING; BRAIN; MALE; NEUROPEPTIDES; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY;

EID: 4043124849     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnr.0000134849.63755.15     Document Type: Article

References (22)

1. Usdin TB, Hoare SRJ, Wang T, Mezey É and Kowalak JA. TIP39: a new neuropeptide and PTH2-recepor agonist from hypothalamus. Nature Neurosci 1999; 2:941-943.
2. Usdin TB, Wang T, Hoare SR, Mezey E and Palkovits M. New members of the parathyroid hormone/parathyroid hormone receptor family: the parathyroid hormone 2 receptor and tuberoinfundibular peptide of 39 residues. Front Neuroendocrinol 2000; 21:349-383.
3. Dobolyi A, Palkovits M and Usdin TB. Expression and distribution of tuberoinfundibular peptide of 39 residues in the rat central nervous system. J Comp Neurol 2003; 455:547-566.
4. Wang T, Palkovits M, Rusnak M, Mezey E and Usdin TB. Distribution of parathyroid hormone-2 receptor-like immunoreactivity and messenger RNA in the rat nervous system. Neuroscience 2000; 100:629-649.
5. Peyron R, Laurent B and Garcia-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol Clin 2000; 30:263-288.
6. Dobolyi A, Ueda H, Uchida H, Palkovits M and Usdin TB. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci USA 2002; 99:1651-1656.
7. Dubuisson D and Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4:161-174.
8. D'Amour FE and Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 77:74-79.
9. Woolfe G and MacDonald AD. The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther 1943; 80: 300-307.
10. LaBuda CJ and Fuchs PN. A behavioral test paradigm to measure the aversive quality of inflammatory and neuropathic pain in rats. Exp Neurol 2000; 163:490-494.
11. LaBuda CJ and Fuchs PN. Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain. Neurosci Lett 2000; 290:137-140.
12. LaBuda CJ and Fuchs PN. Low dose aspirin attenuates escape/avoidance behavior, but does not reduce mechanical hyperalgesia in a rodent model of inflammatory pain. Neurosci Lett 2001; 304:137-140.
13. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20:441-462.
14. Hoare SR, Clark JA and Usdin TB. Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity. J Biol Chem 2000; 275:27274-27283.
15. Melzack R and Wall PD. Pain mechanisms: a new theory. Science 1965; 150:971-979.
16. Price DD and Dubner R. Neurons that subserve the sensory-discriminative aspects of pain. Pain 1977; 3:307-338.
17. Craft RM, Henley SR, Haaseth RC, Hruby VJ and Porreca F. Opioid antinociception in a rat model of visceral pain: systemic vs local drug administration. J Pharmacol Exp Ther 1995; 275:1535-1542.
18. Sluka KA, Rohlwing JJ, Bussey RA, Eikenberry SA and Wilken JM. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists. J Pharmacol Exp Ther 2002; 302:1146-1150.
19. Ma QP, Allchorne AJ and Woolf CJ. Morphine, the NMDA receptor antagonist MK801 and the tachykinin NK1 receptor antagonist RP67580 attenuate the development of inflammation-induced progressive tactile hypersensitivity. Pain 1998; 77:49-57.
20. Borszcz GS. Increases in vocalization and motor reflex thresholds are influenced by the site of morphine microinjection: comparisons following administration into the periaqueductal gray, ventral medulla, and spinal subarachnoid space. Behav Neurosci 1995; 109:502-522.
21. Kupers RC, Konings H, Adriaensen H and Gybels JM. Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain 1991; 47:5-12.
22. Dobolyi A, Palkovits M, Bodnar I and Usdin TB. Neurons containing tuberoinfundibular peptide of 39 residues project to limbic, endocrine, auditory and spinal areas in rat. Neuroscience 2003; 122:1093-1105.